{
  "abstract": "The treatment landscape for multiple sclerosis (MS) has evolved significantly over the years, with an increasing emphasis on adherence and persistence as key factors in optimising therapeutic outcomes.1 While efficacy remains a cornerstone in treatment selection, persistence has emerged as an essential metric for long-term disease control and patient quality of life. As highlighted in recent real-world evidence, cladribine provides a compelling example of a disease-modifying therapy (DMT) that promotes both adherence and persistence, reinforcing its value in MS management.2",
  "authors": [
    {
      "affiliations": [
        "Pharmacy Service, Hospital de Sagunto, Sagunto, Spain"
      ],
      "name": "Joaquin Borrás Blasco"
    },
    {
      "affiliations": [
        "Hospital Universitario Virgen Macarena, Sevilla, Spain"
      ],
      "name": "Vicente Merino-Bohorquez"
    },
    {
      "affiliations": [
        "Pharmacy, Hospital Universitario de la Princesa, Madrid, Spain"
      ],
      "name": "Esther Ramírez Herráiz"
    }
  ],
  "title": "Critical role of persistence and adherence in multiple sclerosis treatment: the value of cladribine",
  "uid": "d076cd44-099f-5440-92f1-63d426152a66"
}